AstraZeneca has been removed from Denmark’s COVID-19 vaccine program, and this was officially announced on Wednesday, April 14. With this decision, the region became the first country to completely abandon this brand of coronavirus shots.
Delayed vaccination schedule
As per Reuters, the move will put off Denmark’s scheduled completion of its AstraZeneca vaccination scheme that was initially set to July 25. The new date has been moved to early August, according to health authorities.
This means that everyone who already has vaccination appointments for AstraZeneca vaccine shots will be canceled and rescheduled. For those who have received the first dose, they will not be getting the pulled-out vaccine anymore, but a new brand will be administered as a second dose.
It was added that those who are 16 years old and above could expect to get an offer for vaccination in late June. The individuals who will accept the offer will be inoculated five weeks later, which is in early August.
Why Denmark ditches AstraZeneca
The Danish Health Authority released a statement and cited rare side effects and others as reasons for the decision to stop administering the AstraZeneca vaccine to the citizens. The agency further explained that while the benefits o- taking the shots outweigh the risks, they still chose to discontinue due to the possible link to rare cases of blood clotting. The health authority added that other vaccines are also available in Denmark, so they could just use this.
"Based on the scientific findings, our overall assessment is there is a real risk of severe side effects associated with using the COVID-19 vaccine from AstraZeneca," DHA’s director-general, Søren Brostrøm, said. "We have, therefore, decided to remove the vaccine from our vaccination program."
He went on to explained, "In the midst of an epidemic, it has been a difficult decision to continue our vaccination program without an effective and readily available vaccine against COVID-19. However, we have other vaccines at our disposal, and the epidemic is currently under control.
Once the administration of COVID-19 vaccines starts again in Denmark, it was said that the Johnson & Johnson brand would be used. In any case, this vaccine was rolled out in Europe and got delayed due to reports of the same blood clotting that was said to have developed in some people who had the AstraZeneca vaccine.


Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
Oil Prices Jump as Middle East Tensions Shake Markets, AI Rally Loses Steam
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
US Launches New Iran Strikes as Strait of Hormuz Conflict Escalates, Oil Prices Rise
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says
SpaceX Stock Draws Bullish Wall Street Coverage Ahead of Nasdaq-100 Inclusion
Asian Stocks Slip as Iran Tensions, Samsung Weakness and Fed Caution Weigh on Markets
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices
European Stocks Hold Steady as Consumer Shares Rise, AI Tech Selloff Weighs on Markets
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
US Back-to-School Spending Seen Falling as Families Focus on Essentials
South Korea’s KOSPI Plunges as Samsung, AI Chip Stocks Trigger Market Sell-Off
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 



